Quantum Computing (QCI) and IPQ Analytics have collaborated on a new technique that can enhance the efficiency and outcomes of clinical trials and diagnostics.
As part of the alliance, IPQ will examine real-world data to create new disease models via the integration of its knowledge graph depiction of the patient journey with QCI’s quantum-driven community detection technology.
Go deeper with GlobalData
The review of complex networks that imitate biological processes and molecular interactions is necessary for drug development, QCI noted.
In addition, understanding these networks’ structure and identifying interconnected communities play an important role.
Graph analytics can aid in assessing patient symptoms and outcomes for medical analysis.
QCI’s QGraph, a Qatalyst component, helps drug analysts address the computationally expensive graph issues.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataWith the collaboration, IPQ will have early access to the QGraph’s QDetect community-detection technology. This will enable ‘next-generation phenotypes’ (NGP) to re-diagnose participants in failed clinical trials to recognise responsive patient subgroups.
NGP can also be used for optimising payor reimbursement guidelines to decrease testing that is not required and ineffective treatment of patients.
It can further improve clinical decision support for early, precise diagnoses and enhanced patient management.
Estimates show that on average, clinical trials cost $1bn but less than 15% are successful.
For pharmaceutical organisations, the new IPQ modelling technique plus Qatalyst is expected to facilitate recovery of failed trials and improving study design.
The approach could allow improved patient diagnosis, treatment and outcomes.
Quantum Computing CEO Robert Liscouski said: “We believe that this new approach, optimised and enhanced with our quantum computing software, has significant clinical and commercial value.
“By enabling more effective patient management and the development of more directed and cost-effective treatments, we are committed to providing value with quantum computing for businesses today.”
The partners will use the new approach created and confirmed by IPQ for reserved ejection heart failure (HFpEF).
